Molecular Biomarkers To Identify Patients (Pts) Who May Benefit From Durvalumab (D; Anti-Pd-L1) +/- Tremelimumab (T; Anti-Ctla-4) In Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma (R/M Hnscc) From Hawk And Condor Studies.

Weimin Li,Athena Matakidou,Zara Ghazoui,Han Si,Sophie Wildsmith, Nassim Morsli,Helen Mann,Magdalena Wrona,Melissa de Los Reyes,Rajiv Raja,Craig Barker,Jessica Whiteley,Qu Zhang,Jerome Fayette,Dan Paul Zandberg,Ricard Mesia,Lillian L. Siu

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 4|浏览5

暂无评分

摘要

6548Background: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T. Methods: In HAWK (NCT02207530), 112 pts (PD-L1 tumor cel...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要